Free Trial

Johnson & Johnson Q1 2025 Earnings Report

Johnson & Johnson logo
$151.62 +2.93 (+1.97%)
Closing price 04/11/2025 03:59 PM Eastern
Extended Trading
$151.68 +0.06 (+0.04%)
As of 04/11/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Johnson & Johnson EPS Results

Actual EPS
N/A
Consensus EPS
$2.59
Beat/Miss
N/A
One Year Ago EPS
N/A

Johnson & Johnson Revenue Results

Actual Revenue
N/A
Expected Revenue
$21.65 billion
Beat/Miss
N/A
YoY Revenue Growth
N/A

Johnson & Johnson Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Tuesday, April 15, 2025
Conference Call Time
8:30AM ET

Conference Call Resources

Remove Ads

Johnson & Johnson Earnings Headlines

Trump to unlock 15-figure fortune for America (May 3rd) ?
We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men in America. Rickards has spent his fifty-year career in the innermost circles of the U.S. government and banking. And he believes Trump could soon release this frozen asset to the public.
See More Johnson & Johnson Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Johnson & Johnson? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Johnson & Johnson and other key companies, straight to your email.

About Johnson & Johnson

Johnson & Johnson (NYSE:JNJ) is a US-based multinational pharmaceutical company that started in the early 1870s. Robert Wood Johnson began training as a pharmacist at 16 and founded his 1st company in 1873. That company would be disbanded by 1886 when Johnson joined his brothers to form today's entity. The company’s first line of products was sterile surgical dressings which were soon followed up by household products and medical guides.

Today, Johnson & Johnson is one of the world’s largest companies. It is ranked 36th on the 2021 Fortune 500 list and is a Dow Jones Industrial Average member. The company operates via 250 subsidiaries with operations in 60 countries and product sales in 175. As of 2021, annual sales were in the range of $95 billion and growing. The company is also a leader in equality and the advancement of women’s rights. Johnson & Johnson’s workforce was nearly 50% female by 1910, and many held significant positions of responsibility.

Among the company’s many advances in health care is the advancement of sterile conditions to prevent postoperative and secondary infections. Products include sterile gauze, cotton and dressings, and the development of the industrial sterilization process. However, the product that launched the company to success was the combination of a sterile dressing with tape. The company called the new products Band-Aids, which is now synonymous with small, prepackaged bandages. Another major win for the company was Johnson & Johnson Baby Soap.

Today, Johnson & Johnson operates in 3 segments: Pharmaceutical, Consumer Health and MedTech. The Consumer Health segment alone covers brands like Aveeno, Listerine, Tylenol, Zyrtec, Band-Aid and Neosporin, which are among the world’s most recognizable brands. The company’s purpose is to “blend science and ingenuity to change the trajectory of health for humanity profoundly”.

The Pharmaceutical segment offers products in all segments of the healthcare spectrum and has partnerships to develop new drugs with at least 10 other major healthcare providers and dozens of smaller research facilities. Products are offered wholesale to retailers and through healthcare systems. The MedTech segment develops and manufactures various healthcare devices and diagnostic tools. Among the many recognizable products from this segment are ACUVUE contact lenses.

Johnson & Johnson went public in 1944 and began paying dividends soon after. The company began increasing its dividend payment in 1962 and has increased it yearly. The company is a member of the Dividend Aristocrat Index and qualifies as a Dividend King with more than 50 years of consecutive annual increases. The company employs more than 142,000 individuals and serves more than 1 billion daily. Regarding the company’s health, its track record of dividend payments is backed up by a AAA credit rating. Johnson & Johnson is one of only 2 US corporations with such a rating and is more trusted than the US government.

The company announced plans to split into two publicly traded companies in 2021. The move is expected to be complete in late 2023 and will result in a Consumer Health company and a Pharmaceutical company.





View Johnson & Johnson Profile

More Earnings Resources from MarketBeat